DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,418 filers reported holding DANAHER CORPORATION in Q3 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $452,967 | +13.2% | 1,811 | +13.1% | 0.08% | +5.1% |
Q1 2024 | $400,234 | +21.8% | 1,601 | +12.8% | 0.08% | +16.2% |
Q4 2023 | $328,612 | -6.7% | 1,419 | 0.0% | 0.07% | -15.0% |
Q3 2023 | $352,054 | +24.6% | 1,419 | +20.7% | 0.08% | +33.3% |
Q2 2023 | $282,558 | -4.8% | 1,176 | 0.0% | 0.06% | -4.8% |
Q1 2023 | $296,717 | -5.7% | 1,176 | -0.8% | 0.06% | -3.1% |
Q4 2022 | $314,819 | +1.2% | 1,185 | -1.4% | 0.06% | -8.5% |
Q3 2022 | $311,000 | +3.0% | 1,202 | +0.8% | 0.07% | -5.3% |
Q2 2022 | $302,000 | -18.4% | 1,192 | -5.5% | 0.08% | -5.1% |
Q1 2022 | $370,000 | -10.8% | 1,261 | 0.0% | 0.08% | 0.0% |
Q4 2021 | $415,000 | -12.1% | 1,261 | -18.6% | 0.08% | -30.7% |
Q3 2021 | $472,000 | +39.2% | 1,550 | +22.9% | 0.11% | +18.8% |
Q2 2021 | $339,000 | +19.4% | 1,261 | 0.0% | 0.10% | +9.1% |
Q1 2021 | $284,000 | +1.4% | 1,261 | 0.0% | 0.09% | +4.8% |
Q4 2020 | $280,000 | +2.9% | 1,261 | 0.0% | 0.08% | -44.7% |
Q3 2020 | $272,000 | +22.0% | 1,261 | 0.0% | 0.15% | +13.4% |
Q2 2020 | $223,000 | +4.7% | 1,261 | -14.4% | 0.13% | +45.7% |
Q3 2019 | $213,000 | -11.2% | 1,473 | -12.1% | 0.09% | -29.2% |
Q2 2019 | $240,000 | – | 1,676 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 263,188 | $33,896,000 | 13.46% |
WALTER & KEENAN WEALTH MANAGEMENT LLC /IN/ /ADV | 263,188 | $33,896,000 | 13.46% |
Defender Capital, LLC. | 127,230 | $17,610,000 | 12.86% |
Eos Focused Equity Management, L.P. | 53,908 | $7,461,000 | 11.12% |
CORTLAND ASSOCIATES INC/MO | 419,035 | $57,999,000 | 10.88% |
Mirova US LLC | 477,368 | $66,072,000 | 8.75% |
Pactiv General Employee Benefit Trust | 579,300 | $80,181,000 | 8.58% |
Riverstone Advisors, LLC | 57,623 | $7,976,000 | 8.07% |
Eversept Partners, LP | 233,957 | $32,419,197 | 8.06% |
Third Point | 3,570,000 | $494,124,000 | 7.88% |